Updated 0 sec ago

Stocks

NamePrice24h ChangeMarket Cap24h High / Low7d Change
S&P 500$7,723.97▲ 0.07%—H 7,738 / L 7,670▼ -1.12%
Nasdaq 100$29,745.60▼ -0.69%—H 29,854 / L 29,408▼ -3.68%
Dow Jones$52,053.16▲ 0.84%—H 52,197 / L 51,681▲ 0.77%
AAPL$344.30▲ 0.39%$5.02TH 347.85 / L 342.59▲ 2.27%
MSFT$539.58▲ 1.10%$4.01TH 540.48 / L 531.22▲ 0.84%

US market data via Stooq · Yahoo Finance · Nasdaq · USD

Crypto

NamePrice24h ChangeMarket Cap24h High / Low7d Change
BTC Bitcoin$82,031.00▲ 0.07%$1.65TH 82,436 / L 79,806▲ 1.27%
ETH Ethereum$2,432.05▼ -0.71%$297.06BH 2,441 / L 2,325▼ -0.17%
XRP$1.3400▼ -0.17%$84.31BH 1.3400 / L 1.2900▼ -0.83%
SOL Solana$105.52▲ 0.32%$62.18BH 106.03 / L 100.99▼ -2.83%
DOGE Dogecoin$0.0806▼ -2.97%$12.61BH 0.0822 / L 0.0779▼ -2.41%

Live prices via CoinGecko · USD

Lilly’s once-weekly basal insulin approved

Viewing 1 post (of 1 total)
  • Author
    Posts
  • #341
    Master
    Keymaster
    👑 Lv.100 Master

    The QWINT program, with more than 3,400 participants, showed noninferior A1c control versus once-daily insulin.

    Market impact: Positive for Lilly’s diabetes franchise and likely to accelerate competition on dosing convenience.

    Source: Medscape · Caution · Section: Health, Macro & Commodities

Viewing 1 post (of 1 total)

Join Bull Lounge to participate — Log in / Register

Today's visitors 53 · Online 0
Scroll to Top